BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.